SynGenSys creates product-specific libraries of synthetic genetic parts for next-generation biomedicines and biomanufacturing processes.
Our philosophy is simple: all products and production processes are unique. Therefore core genetic assemblies used for therapy or biomanufacturing should harbour custom synthetic DNA parts and circuits designed to be fit for a specific purpose.
SynGenSys Technology Platform
Our platform technology harnesses years of research and development with bioindustrial partners. We engineer novel synthetic genetic parts from the ground-up, based on bioinformatic analysis of streams of genome-scale information pertinent to the biological system and user-defined design criteria.
DNA Engineering for Manufacturability: Biologics Production
Recombinant DNA constructs used to engineer a mammalian cell factory are at the core of a biomanufacturing process.
However, next generation protein biopharmaceuticals or gene therapies are inherently variable, can be difficult to manufacture and generic, one-size-fits-all genetic vectors cannot be optimal in all cases. Expanding the manufacturability design space, our platform creates new DNA parts that re-programme key synthetic processes to speed cellular production.
SynGenSys Ltd. and Takeda Ventures, Inc. announce a strategic collaboration aimed at the development of novel cell-type specific synthetic promoters to support development of Takeda’s pipeline of innovative cell and gene therapies.
Professor David James, Chief Scientific Officer of SynGenSys: “This is an incredibly exciting opportunity for SynGenSys. We will work closely with Takeda to design new synthetic DNA components that provide targeted and controlled expression of therapeutic transgenes only where they are needed, avoiding non-specific cytotoxicity in non-diseased cells and tissues”.
“Takeda has established a world-class network of collaborators including a research partnership with Syngensys, where we are jointly leveraging our expertise to construct precision targeted gene therapy,” said Dr Victor Stone, Senior Investment Director and Partner, Takeda Ventures Inc. “Our collaboration and investment in Syngensys enables Takeda’s capabilities in synthetic promoters to advance next-generation gene therapies.”.
SynGenSys Ltd. 5th Floor, 3 St. Paul’s Place, 129 Norfolk Street, Sheffield S1 2JE, United Kingdom